Group 1 - The stock of Valiant Pharmaceuticals (09887) has increased by over 5%, currently trading at 72.5 HKD with a transaction volume of 86.43 million HKD [1] - On August 14, the company announced the completion of patient enrollment for the pivotal single-arm clinical study of Opalizumab (LBL-024), a PD-L1/4-1BB bispecific antibody [1] - Opalizumab (LBL-024) is the first bispecific antibody targeting both PD-L1 and 4-1BB, currently in pivotal clinical stages, and is expected to be the first approved drug for treating EP-NEC [1] Group 2 - The 4-1BB agonist can reactivate apoptotic T cells and significantly expand their numbers, making it particularly suitable for treating PD-1/PD-L1 resistant or ineffective cold tumors [2] - Besides EP-NEC, Opalizumab has received approval for clinical studies in several cancers with high unmet clinical needs, including small cell lung cancer (SCLC), biliary tract cancer (BTC), ovarian cancer (OC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), liver cancer (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), and malignant melanoma [2] - Promising clinical results have been observed in multiple cancer types such as SCLC, BTC, and OC, indicating the potential of Opalizumab as an effective anti-tumor drug with broad indications [2]